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Background:  Lowering systolic pressure (SBP) to ≤130 mm Hg in LIFE was not associated with lower cardiovascular (CV) risk and was associated 
with increased mortality risk in the LIFE trial. We hypothesized that persistence of ECG left ventricular hypertrophy (LVH) would identify a subset of 
patients at increased risk of CV morbidity and CV and all-cause mortality.
Methods:  Risks of stroke, MI, CV death, the composite endpoint of these events, and all-cause mortality were examined in relation to the presence 
of LVH by mean in-treatment Cornell product (CP) in 463 hypertensive patients with mean SBP ≤130 mm Hg during randomly assigned losartan- or 
atenolol-based treatment.
Results:  During mean follow-up of 4.4±1.3 years, persistence of mean CP ≥2440 mm·msec was associated with significantly higher 4-year rates 
and univariate risks of CV death, MI, stroke, the composite endpoint and all-cause mortality. In multivariate Cox analyses adjusting for randomized 
treatment, Framingham risk score and in-treatment diastolic BP, persistence of CP LVH remained associated with statistically significant 73 to 261% 
increased risks of all endpoints.
Conclusions:  Persistence of CP LVH among hypertensive patients with greater lowering of SBP (mean achieved SBP ≤130) is associated with 
significantly higher risk of CV morbidity and CV and all-cause mortality. These findings suggest that persistence of LVH in a patient subset may in part 
explain the lack of benefit seen in hypertensive patients despite treatment to lower SBP.
Outcome in Relation to Perstence of Cornell Product LVH
Outcome
4-Year Event Rates (%) Univariate Cox Models Multivariate Cox Models
LVH- (n=252) LVH+ (n=211) p value HR 95% CI p value HR 95% CI p value
CV death 3.4 8.9 0.003 3.05 1.41-6.63 0.005 3.07 1.14-6.69 0.005
MI 3.3 7.0 0.010 2.84 1.24-6.54 0.014 2.65 1.14-6.16 0.024
Stroke 2.1 8.5 0.002 3.81 1.51-9.59 0.005 3.61 1.42-9.12 0.007
Composite Endpoint 7.0 20.0 <0.001 3.26 1.89-5.64 <0.001 3.10 1.79-5.38 <0.001
All-cause mortality 10.0 14.9 0.015 1.71 1.07-2.74 0.026 1.73 1.08-2.72 0.023
